Emalex Awarded U.S. Patent for Its Orally Disintegrating Ecopipam Formulation
Emalex Biosciences has announced a significant advancement in its drug development efforts with the issuance of a new patent by the U.S. Patent and Trademark Office. The patent covers an orally disintegrating tablet (ODT) formulation of ecopipam, an investigational therapy currently being developed for the treatment of Tourette syndrome. This milestone highlights the company’s ongoing commitment to improving both treatment accessibility and patient experience through innovative pharmaceutical design.
Ecopipam is a selective dopamine D1 receptor antagonist, a mechanism that distinguishes it from many currently approved treatments for Tourette syndrome, which primarily target dopamine D2 receptors. By focusing on D1 receptor modulation, ecopipam represents a novel therapeutic approach that may offer meaningful benefits for patients who have not responded adequately to existing therapies or who have experienced intolerable side effects.
The newly granted patent specifically pertains to an orally disintegrating tablet formulation, which is designed to dissolve quickly in the mouth without the need for water. This type of dosage form can be particularly beneficial for pediatric populations and individuals who have difficulty swallowing conventional tablets. For patients living with Tourette syndrome—a condition that often begins in childhood and can involve involuntary motor and vocal tics—ease of administration can play a critical role in treatment adherence and overall quality of life.
Eric Messner, CEO of Emalex Biosciences, emphasized the broader significance of this development. He noted that while drug efficacy is paramount, the method of delivery can be equally important in ensuring successful treatment outcomes. “Developing alternative dosage forms is a long-term investment,” Messner stated, “because the way a medicine is administered can have a major impact on patient acceptance and consistency of use.” He added that the patent reflects the company’s strategic formulation efforts, while parallel initiatives such as expanded access programs demonstrate its patient-centric approach.
Looking ahead, Emalex plans to advance the ODT formulation through a structured development pathway. This process will include key stages such as process optimization, scale-up for manufacturing, and production under current Good Manufacturing Practice (cGMP) standards. Additional studies will evaluate the stability of the formulation to ensure it maintains its safety and efficacy over time. A first-in-human pharmacokinetic study is anticipated to begin in late 2026 or early 2027, marking an important step toward clinical validation.
The planned clinical program will compare the performance of low-dose ODT versions of ecopipam with its existing immediate-release tablet formulation. Researchers will assess pharmacokinetic parameters, as well as tolerability and palatability—critical factors for patient acceptance, particularly in younger populations. These studies are expected to provide valuable insights into whether the ODT formulation can deliver comparable therapeutic benefits while enhancing convenience and usability.
In parallel with its formulation development efforts, Emalex Biosciences is also expanding patient access to ecopipam through its Expanded Access Program (EAP). This initiative is designed to provide treatment options for individuals who have exhausted currently approved therapies and are unable to participate in clinical trials. The program aims to enroll up to 200 patients across multiple sites in the United States, reflecting growing demand and continued progress in the company’s access strategy.
Eligibility for the Expanded Access Program is determined on a case-by-case basis and requires physician oversight, authorization from the U.S. Food and Drug Administration, and approval from an Institutional Review Board (IRB). Physicians can request access to ecopipam for patients who have previously been treated with FDA-approved medications for Tourette syndrome—including aripiprazole, haloperidol, or pimozide—and who have experienced inadequate response, safety concerns, or limited access to those treatments.
Tourette syndrome is a chronic neurodevelopmental condition characterized by repetitive, involuntary movements and vocalizations known as tics. These symptoms can vary in severity and frequency, often interfering with daily activities such as school, work, and social interactions. While several treatment options are available, many patients continue to struggle with incomplete symptom control or adverse side effects, underscoring the need for new therapeutic approaches.
Through its dual focus on innovative drug formulation and expanded patient access, Emalex Biosciences is working to address critical gaps in the current treatment landscape. The ODT formulation of ecopipam represents not only a scientific advancement but also a practical solution aimed at improving the patient experience. At the same time, the Expanded Access Program ensures that patients with limited options have an opportunity to benefit from investigational therapies while formal clinical development continues.
As the company moves forward with its clinical and regulatory plans, this latest patent milestone reinforces its commitment to advancing care for individuals living with Tourette syndrome and delivering innovative solutions that prioritize both efficacy and ease of use.
About Ecopipam
Ecopipam is a first-in-class investigational compound that is being studied as a potential treatment for certain central nervous system (CNS) disorders. It blocks the actions of the neurotransmitter dopamine at the D1 receptor. Dopamine is a neurotransmitter in the central nervous system, and its receptors have been classified into two “families” based on their genetic structure: “D1” (including subtypes D1 and D5) and “D2” (including subtypes D2, D3, and D4). D1 receptor super-sensitivity may be a mechanism for the repetitive and compulsive behaviors associated with Tourette syndrome.
Currently approved therapies for the treatment of Tourette syndrome act at D2 receptors. Ecopipam has been shown to be generally well tolerated in clinical trials conducted to date and has received Orphan Drug and Fast Track designation from the FDA for the treatment of pediatric patients with Tourette syndrome. Adverse events affecting primarily the central nervous system have been reported in clinical trials conducted to date, including headache, fatigue, somnolence, insomnia, restlessness, anxiety, depression and rarely, suicidal ideation.
About Emalex Biosciences
Emalex Biosciences was created by Paragon Biosciences to develop new treatments for central nervous system disorders. The company is advancing a new class of therapy for patients with Tourette syndrome and other conditions with limited treatment options. Learn more at https://emalexbiosciences.com.
About Paragon Biosciences
Paragon Biosciences, founded by Jeff Aronin, creates, builds and funds innovative biology-based companies. Its portfolio companies advance scientific breakthroughs aimed at addressing significant unmet medical needs.
Source Link:https://www.businesswire.com/
